Development of Effervescent Tablets of Alendronate Sodium with Improved Intestinal Permeation

Alendronate sodium

DOI:

https://doi.org/10.37285/ijpsn.2018.11.1.7

Authors

  • Prasad Vure
  • Sundeep Chaurasia

Abstract

The aim of the present study is to develop effervescent tablets of alendronate sodium to improve their intestinal permeability to treat osteoporosis. Effervescent tablets of alendronate sodium were developed with different ratios of acid to alkaline components having a pH of about 3 to about 6.5. The tablets were prepared by direct compression method. The physical mixture blend was evaluated for angle of repose, true density, bulk density, compressibility index. The formulated tablets were subjected to thickness, weight variation, hardness, friability, drug content and pH. The in vitro dissolution studies were carried out using the USP Type 2 apparatus. Formulation F14 was considered as optimized formulation because it shows drug release pattern higher than that of the other formulations and conventional marketed formulation. Ex vivo permeation studies were performed for the optimized formulation (F14) and that of the conventional marketed formulation. The drug release of the formulation (F14) was higher than the marketed formulation. Accelerated stability studies of the optimized formulation indicated that there were no signs of visually distinguishable changes, drug content and in vitro dispersion time. Thus, an increase in drug release may enhance absorption, in turn may enhance bioavailability.       



Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Keywords:

Effervescent tablet, Alendronate sodium, Dissolution study, Intestinal permeability

Downloads

Published

2018-01-31

How to Cite

1.
Vure P, Chaurasia S. Development of Effervescent Tablets of Alendronate Sodium with Improved Intestinal Permeation: Alendronate sodium. Scopus Indexed [Internet]. 2018 Jan. 31 [cited 2024 May 18];11(1):3990-7. Available from: http://www.ijpsnonline.com/index.php/ijpsn/article/view/354

Issue

Vol. 11 No. 1 (2018): January-February 2018

Section

Research Articles
Crossref
Scopus
Google Scholar
Europe PMC

References

Gande S and Rao Y (2011). Sustained-release effervescent floating matrix tablets of baclofen: development, optimization and in vitro-in vivo evaluation in healthy human volunteers. Daru: Journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 19(3): 202-9.
Gurrapu A, Jukanti Raju, Sharan Reddy Bobbala, Swetha Kanuganti and Jyothi (2011). Improved oral delivery of valsartan from maltodextrin based proniosome powders. Advanced Powder Technology 23(5): 583-590
Koba M, Katarzyna Koba and Lech Przyborowski (2008). Application of UV-Derivative Spectophotometry for Determination of Some Bisphosphonates Drugs in Pharmaceutical Formulations. Acta Poloniae Pharmaceutica-Drug Research 65(3): 289-294
Kusamori K (2010). Development of a novel transdermal patch of alendronate, a nitrogen-containing bisphosphonate, for the treatment of osteoporosis. Journal of Bone and Mineral Research 25(12): 2582-91.
Lin, JH, Chen I-W and Deluna FA (1994). On the absorption of alendronate in rats. J. Pharm. Sci 83: 1741-1746.
Nanjwade BK (2012). Development and Evaluation of Gastro-retentive Floating Tablets of Glipizide Based on Effervescent Technology. J Drug Metab Toxicol 3(3): 3-121.
Negi JS (2011). Effect of bioadhesion on initial in vitro buoyancy of effervescent floating matrix tablets of ciprofloxacin HCL. Journal of Advanced Pharmaceutical Technology & Research 2(2):121-127.
Patel JK and Chavda JR (2010). Formulation and Evaluation Bioadhesive Tablets of Glipizide. Braz Arch Biol Technol 53(5): 1073-1085
Porras AG, Holland SD and Gertz BJ (1999). Pharmacokinetics of alendronate.Clin Pharmacokinet. 36(5): 315-28.
Rajab M and Jouma M (2010). Optimization of a metformin effervescent floating tablet containing hydroxypropylmethyl cellulose and stearic acid. Die Pharmazie 9: 97-101.
Ravi Kumar, Patil MB, Patil SR, Mahesh S and Paschapur S (2009). Formulation and evaluation of effervescent floating tablets of Famotidine. International Journal of Pharm Tech Research, 1(3):754-763.
Rosen C (2003). Effervescent compositions comprising bisphos-phonates and methods related thereto, US 7,488,496 B2.
Rosen C (2006). Effervescent compositions comprising bisphos-phonates and methods related thereto, US 7,964,212 B2.
ShirsandSB, Swamy PV, Kusum Devi V and Sarasija Suresh (2011). Formulation Design and Optimization of Fast Dissolving Effervescent Tablets of Clonazepam. RGUHS Journal of Pharmaceutical Sciences, 1(3): 202-208:
Witry MJ and Doucette WR (2014). Community pharmacists, medication monitoring, and the routine nature of refills. J Am Pharm Assoc 54(6): 594-603.
Zade P, Kawtikwar P and Sakarkar D (2009). Formulation, evaluation and optimization of fast dissolving tablet containing tizanidine hydrochloride. Int J Pharm Tech Res 1(1): 34-42.